Zeb Hussain | Biology and Life Sciences | Research Hypothesis Excellence Award

Published on by Research Hypothesis

Dr. Zeb Hussain | Biology and Life Sciences | Research Hypothesis Excellence Award

Dr. Zeb Hussain | Biology and Life Sciences | Research Hypothesis Excellence Award | Lecture | Dow university of health sciences | Pakistan

Dr. Zeb Hussain is an accomplished microbiologist, medical laboratory scientist, and researcher whose work bridges advanced diagnostic microbiology, infectious disease surveillance, molecular epidemiology, and clinical laboratory quality systems. Dr. Zeb Hussain holds an M.Phil. in Pathology (Microbiology) from Dow University of Health Sciences and is currently pursuing a Ph.D. in Microbiology at the University of Karachi with a research focus on the molecular characterization and phylogenetic analysis of carbapenemase-producing bacteria associated with ventilator-acquired pneumonia. His academic foundation also includes a BS in Medical Laboratory Technology, a BSc in Chemistry and Biology, an Executive MBA in Health Management, and professional certification in ISO-15189:2012 assessor training from the Pakistan National Accreditation Council, equipping him with both scientific depth and managerial competence. Professionally, Dr. Zeb Hussain has extensive experience as a Medical Technologist and Shift Supervisor at the Dow Diagnostic and Research Complex, where he oversees microbiology operations including bacterial and fungal culture interpretation, parasitology, serology, PCR-based molecular diagnostics, biosafety practices, quality assurance, ISO compliance, and laboratory workflow management. His managerial expertise extends to inventory oversight, vendor coordination, LIS operations, staff supervision, and patient-physician issue resolution, ensuring efficient clinical service delivery. As an educator, he has taught medical and health sciences students at Malir University of Science and Technology and conducted MBBS/BDS tutorials at Dow University of Health Sciences, contributing to academic capacity building in laboratory sciences. His research interests include antimicrobial resistance, multidrug-resistant gram-negative pathogens, genotyping of bacterial and viral organisms, clinical-environmental surveillance, and epidemiological modelling of infectious diseases. Dr. Zeb Hussain’s research skills encompass molecular diagnostics, PCR, DNA/RNA extraction, immunoassay evaluation, culture and sensitivity testing, laboratory biosafety, and use of automated biochemical and hematology analyzers. He has presented his research internationally, including at the European Congress of Immunology in Vienna, and has contributed to several peer-reviewed publications in Scopus-indexed journals in areas such as measles sero-surveillance, invasive blood culture pathogens, uropathogens, and antimicrobial resistance patterns. His awards and recognitions include international poster and oral presentation selections, reflecting his active role in global scientific exchange. Dr. Zeb Hussain continues to advance clinical microbiology through his dedication to infectious disease research, laboratory quality enhancement, and academic mentorship, demonstrating strong commitment to improving public health outcomes and clinical microbiological practices within Pakistan and beyond.

Profile:  orcid

Featured Publications

  1. Hussain, Z., Farooqui, F., Ibrahim, A., & Baig, S. (2025). Patients and surfaces: Integrated clinical–environmental surveillance of MDR gram-negative bacteria in critical-care units (Karachi). Microorganisms.

  2. Hussain, Z., Naim, A., Fatima, A., Karim, A., Uddin, F., & Shams, S. (2025). Distribution of MBL and serine-β-lactamase-producing pathogens in ventilator-associated pneumonia: Insights into MDR and XDR strains. Iranian Journal of Microbiology.

  3. Hussain, Z. (2024). Sero-surveillance of measles virus seropositivity amongst vaccinated children of rural areas of Sindh. Microbiological & Immunological Communications.

  4. Fatima, A., Iffat, W., Dawood, K., Sarfaraz, S., Hussain, Z., Siddiqui, H. Z., & Gajdács, M. (2023). Prevalence and antimicrobial resistance of uropathogens in Karachi, Pakistan. Acta Biologica Szegediensis.

  5. Fatima, A., Gohar, H., Dawood, K., Sajjad, M., Fasih, F., & Hussain, Z. (2022). Distribution of invasive pathogenic isolates in blood culture with their antimicrobial susceptibility pattern in a diagnostic lab in Karachi. Journal of the Pakistan Medical Association.

  6. Hussain, Z. (2020). Measles in Sindh, Pakistan. Journal of the Pakistan Medical Association (Submission ID: JPMA-2020-2312).

  7. Hussain, Z. (Year not specified). Sero-surveillance of measles virus amongst vaccinated children of rural areas of Sindh, Pakistan. Unpublished conference research.

 

Muhammad Bilal Afridi | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Dr. Muhammad Bilal Afridi | Medicine and Health Sciences | Best Researcher Award

Dr. Muhammad Bilal Afridi | Medicine and Health Sciences | Best Researcher Award | Pharmaceutical | Abdul Wali Khan University Mardan | Pakistan

Dr. Muhammad Bilal Afridi is a dedicated pharmaceutical scientist and clinical pharmacist recognized for his expertise in drug synthesis, pharmacological modeling, and computational chemistry. With a profound academic background and more than a decade of professional experience, Dr. Afridi has established himself as a leading researcher in the domain of synthetic and therapeutic drug development. He earned his Ph.D. in Pharmaceutical Sciences from Abdul Wali Khan University, Mardan, where his doctoral research focused on the synthesis, characterization, computational studies, and pharmacological potential of synthetic curcumin derivatives aimed at addressing diabetes and amnesia-related disorders. His earlier academic milestones include an M.Phil in Pharmaceutical Sciences from Abdul Wali Khan University and a Doctor of Pharmacy (Pharm-D) from Kohat University of Science and Technology. Professionally, Dr. Muhammad Bilal Afridi has served as a pharmacist at the Institute of Kidney Diseases (IKD), Peshawar, where he managed hospital pharmacy operations, clinical pharmacy services, and patient safety programs. His leadership extended to training junior pharmacists, supervising pharmacy interns, and participating in institutional Drug and Therapeutic Committees. His previous tenures at Rehman Medical Institute and D. Watson Chemist allowed him to develop robust skills in patient counseling, prescription review, pharmacovigilance, and rational drug use. Dr. Afridi’s research interests encompass computational drug design, molecular docking, pharmacodynamics, and synthesis of bioactive compounds, reflecting his interdisciplinary approach that bridges chemistry, pharmacology, and computational biology. His published works in highly regarded journals, including Computational Biology and Chemistry, Inorganic Chemistry Communications, and Current Molecular Pharmacology, contribute significantly to advancing medicinal chemistry and pharmaceutical innovation. He has demonstrated strong analytical and technical skills in density functional theory (DFT) modeling, ADMET prediction, and spectral analysis. Dr. Muhammad Bilal Afridi’s professional competencies include teaching, mentoring, research supervision, and scientific writing, backed by proficiency in tools like EndNote and MS Office. His contributions have been acknowledged through multiple peer-reviewed publications, collaborations with international researchers from Türkiye and Saudi Arabia, and recognition in academic circles for his commitment to scientific excellence. He continues to serve as a role model for young researchers in Pakistan through his dedication to patient-centered research and academic mentorship. His unwavering commitment to bridging pharmaceutical sciences and clinical applications makes him a strong candidate for recognition in global research excellence. Dr. Muhammad Bilal Afridi stands as an emerging leader with a promising future in international pharmaceutical research, committed to innovation, integrity, and impactful contributions to human health and medicine.

Profile: Scopus

Featured Publications 

  1. Afridi, M. B., Sardar, H., Serdaroğlu, G., Shah, S. W. A., Alsharif, K. F., & Khan, H. (2024). SwissADME studies and density functional theory (DFT) approaches of methyl substituted curcumin derivatives. Computational Biology and Chemistry, 112, 108153. (Cited by 8)

  2. Afridi, M. B., Sardar, H., Serdaroğlu, G., Shah, S. W. A., Alsharif, K. F., & Khan, H. (2024). In silico ADMET and DFT analysis of methoxy substituted curcumin derivatives. Inorganic Chemistry Communications, 168, 112943. (Cited by 6)

  3. Afridi, M. B., Khan, H., Ali Shah, S. W., Zafar, M., Almalki, A. S., Ghias, M., & Rahman, N. (2022). In-vivo anti-nociceptive activities of Schiff bases aldehyde derivatives of 4-aminoantipyrine and their molecular docking studies. Main Group Chemistry, 21(2), 373–386. (Cited by 10)

  4. Afridi, M. B., Khan, H., Akkol, E. K., & Aschner, M. (2021). Pain perception and management: Where do we stand? Current Molecular Pharmacology, 14(5), 678–688. (Cited by 25)

  5. Afridi, M. B., Sardar, H., Shah, S. W. A., Serdaroğlu, G., & Khan, H. (2025). Exploring anticholinergic and anti-amnesic potential of methyl substituted monocarbonyl curcumin derivatives. European Journal of Pharmacology, 950, 182653. (Cited by 2)

  6. Afridi, M. B., Khan, H., & Shah, S. W. A. (2023). Computational evaluation of synthetic curcumin analogs for neuroprotective potential using molecular docking approaches. Journal of Molecular Structure, 1287, 135623. (Cited by 4)

  7. Afridi, M. B., Sardar, H., & Khan, H. (2023). Pharmacological insights into curcumin derivatives: A computational and experimental perspective. Bioorganic Chemistry, 137, 106707. (Cited by 3)

 

Graciela Castro Escarpulli | Biology and Life Sciences | Best Researcher Award

Published on by Research Hypothesis

Graciela Castro Escarpulli | Biology and Life Sciences | Best Researcher Award

Prof. Dr Graciela Castro Escarpulli, Escuela Nacional de Ciencias Biológicas IPN, Mexico

Prof. Dr. Graciela Castro Escarpulli is a renowned professor and researcher at the National School of Biological Sciences, IPN, specializing in Medical Bacteriology and Molecular Biomedicine. She leads multiple research lines using conventional and molecular methods to identify infectious bacteria. With 145 undergraduate theses, 44 master’s, and 18 doctoral theses directed, her contributions include 114 publications, 33 book chapters, and 342 conference presentations. A pioneer in CRISPR-Cas for bacterial typing, she has received numerous awards, including the IPN Research Award and the Lázaro Cárdenas Medal. She is a member of the National System of Researchers (Level 2) since 2006. 🧬🔬📚🏅

Publication Profile

Orcid

Academic & Research Background

Prof. Dr. Graciela Castro Escarpulli is a distinguished professor and researcher at the National School of Biological Sciences, IPN. With expertise in diagnostic medical bacteriology and molecular biomedicine, she has significantly contributed to the field. Her research focuses on both conventional and molecular methods for identifying bacteria responsible for infectious diseases. Through her leadership, she has driven various research lines, advancing diagnostic techniques and improving public health outcomes. Prof. Dr. Castro Escarpulli’s work continues to have a profound impact on medical microbiology, enhancing our understanding of bacterial infections. 🧬🔬🦠👩‍🔬

Achievements & Recognition 

Prof. Dr. Graciela Castro Escarpulli is an accomplished academic with an impressive track record. She has supervised 145 bachelor’s theses, 44 master’s theses, and 18 doctoral theses. With 114 indexed papers, 33 book chapters, and 342 global presentations, her expertise spans multiple disciplines. Prof. Castro Escarpulli holds one international patent and has 849 sequences deposited in NCBI, showcasing her contributions to scientific research. Her work continues to make a significant impact in her field, both through academic achievements and innovation. 📚🎓🌍🧬🔬📑

Awards & Contributions 

Prof. Dr. Graciela Castro Escarpulli is a renowned researcher and a pioneer in using the CRISPR-Cas system for bacterial typing. She has received several prestigious awards, including the IPN Research Award, the National Technological Innovation Award, and the Lázaro Cárdenas Medal 🏅. Dr. Castro Escarpulli is highly regarded for her contributions to microbiology and biotechnology 🌱. As a frequent speaker at global conferences 🌍, she continues to influence scientific advancements in her field. Her work exemplifies innovation and dedication to improving scientific understanding, particularly in microbial genetics 🧬.

Research Focus

Prof. Dr. Graciela Castro Escarpulli’s research focuses on microbiology, particularly infectious diseases, and the study of pathogens through advanced genetic analysis techniques. Her work includes the use of massive sequencing to identify unusual bacteria in pyogenic liver abscesses, which may not be detected by classical culture methods. She also explores the genetic makeup of pathogens like Acinetobacter baumannii and Candida spp., as well as antimicrobial resistance in Escherichia coli. Her studies contribute to understanding disease mechanisms, improving diagnostics, and combating antimicrobial resistance. 🔬🦠💉🧬

Publication Top Notes

Massive Sequencing of V3-V4 Hypervariable Region in Pyogenic Liver Abscesses Reveals the Presence of Unusual Bacteria Not Detected by Classical Culture Methods

Multidisciplinary Approach of a Male Case of Imported Malaria, HIV Chronic Infection, and Latent Syphilis

Comprehensive comparative analysis of the periodontal pathogen Porphyromonas gingivalis: exploring the pan-genome, the reconstruction of the gene regulatory network and genome-scale metabolic network

The CRISPR–Cas system in clinical strains of Acinetobacter baumannii: an in-silico analysis

Typing of Candida spp. from Colonized COVID-19 Patients Reveal Virulent Genetic Backgrounds and Clonal Dispersion

Genomic Analysis of Multidrug-Resistant Escherichia coli Strains Isolated in Tamaulipas, Mexico

ESKAPE bacteria characterization reveals the presence of Acinetobacter baumannii and Pseudomonas aeruginosa outbreaks in COVID-19/VAP patients

Disinfection efficacy of ozone on ESKAPE bacteria biofilms: Potential use in difficult-to-access medical devices

Impact of the modification of a cleaning and disinfection method of mechanical ventilators of COVID-19 patients and ventilator-associated pneumonia: One year of experience

Hiranmoy Das | Biology and Life Sciences | Lifetime achievement Award

Published on by Research Hypothesis

Hiranmoy Das | Biology and Life Sciences | Lifetime achievement Award

Prof Hiranmoy Das, Texas Tech University Health Sciences Center, United States

Prof. Hiranmoy Das, MSc, PhD, FAHA, is a renowned biochemist and pharmacologist with a distinguished career. He holds a Ph.D. from the University of Calcutta and has postdoctoral training from prestigious institutions like Harvard Medical School and the Hyogo Institute of Clinical Research. Currently a Professor at Texas Tech University, his research focuses on cardiovascular stem cell therapies, regenerative medicine, and immunology. He has received numerous awards, including induction into the National Academy of Inventors and the American Heart Association. Prof. Das has authored several publications and holds multiple patents. 🌟📚💉🔬🧬

Publication Profile

Google Scholar

Education

Prof. Hiranmoy Das holds a Ph.D. in Biochemistry from the University of Calcutta (1995) and has extensive academic training in zoology, advanced cytogenetics, immunology, and biology. He completed postdoctoral fellowships at prestigious institutions, including Harvard Medical School (1999-2002) and Hyogo Institute of Clinical Research, Japan (1996-1999). Prof. Das has held prominent roles, such as Professor at Texas Tech University (2016-present) and Associate Professor at The Ohio State University (2008-2016). He also directed cardiovascular stem cell research laboratories. His remarkable career spans over decades, focusing on innovative research in the fields of biochemistry and immunology. 📚💉🔬

Honors and Awards

Prof. Hiranmoy Das, a distinguished researcher and educator, has received numerous accolades for his groundbreaking contributions. In 2024, he was elected as a Fellow of the National Academy of Inventors. He was inducted into the prestigious Sigma Xi in 2023 and awarded the President’s Excellence in Research Award in 2022. As a tenured professor at Texas Tech University, he earned the Chancellor’s Council Distinguished Research Award in 2021. His honors also include the American Heart Association Fellowship (2021) and a Keynote Speaker role at an International Conference in 2018. Earlier awards include the NIH K01 Award and National Merit Scholarship. 🏆🔬🎓

Experiences

Prof. Hiranmoy Das has taught a variety of undergraduate, graduate, and professional courses at TTUHSC, including leadership roles in Pharmaceutical Sciences Research (G) in Spring, Summer, and Fall sessions from 2021 to 2024 📚. He led courses like Clinical Correlation-6 and Integrated Therapy and Practice VII, as well as Experimental Design and Biostatistics 🧪. Prof. Das has mentored students in clinical and research settings, contributing significantly to pharmaceutical education 💡. His commitment to fostering academic growth is reflected in his continued leadership in research-focused courses, impacting future professionals in the field of pharmaceutical sciences 🎓.

PhD Thesis

Prof. Hiranmoy Das appears to be heavily involved in mentoring and advising graduate students, particularly in the fields related to pharmacy, veterinary medicine, and health sciences. His research likely focuses on advanced pharmaceutical sciences, drug development, and therapeutics. With his role in advising students pursuing PhD and MS theses, his research could be centered around pharmaceutical applications, medicinal chemistry, or pharmacology. Given his involvement in both veterinary and pharmacy programs, his research may also bridge the gap between human and veterinary health, focusing on biomedical sciences, drug formulations, and therapeutics for both sectors. 📚💊🐾👩‍🔬👨‍🔬

Research Focus

Hiranmoy Das focuses on molecular and cellular biology, particularly related to vascular biology, immunology, and inflammation. His research delves into the roles of Kruppel-like factor 2 (KLF2) in endothelial cells, immune responses, and its regulatory functions in cardiovascular health. He also investigates autophagy, cell death, and ischemic stroke therapies, emphasizing the use of assays for monitoring these processes. His work highlights the role of phytochemicals in cancer prevention and the immune system’s effector functions. Das has made significant contributions to understanding cellular signaling and disease mechanisms, with implications for therapeutic development. 🔬💉🧬🫀

Publication Profile

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes

Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes

Current advances in ischemic stroke research and therapies

MICA engagement by human Vγ2Vδ2 T cells enhances their antigen-dependent effector function

Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells

Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes

CD1-mediated γ/δ T cell maturation of dendritic cells

 

 

Mohamed Houta | Biology and Life Sciences | Best Researcher Award

Published on by Research Hypothesis

Mohamed Houta | Biology and Life Sciences | Best Researcher Award

Mr Mohamed Houta, Beni Suef University, Egypt

Mohamed Houta appears to be a strong candidate for the Research for Best Researcher Award based on his extensive experience and contributions in the field of vaccinology, particularly related to poultry diseases

publication profile

google scholar

Solid Background in Immunology and Vaccinology

Mohamed has a robust foundation in immunology and vaccine research, which is evident from his current role as a Scientific Affairs Manager at Klybeck Life Sciences and his prior experience at MEVAC for Vaccines. His focus on inactivated and live poultry vaccines, conducting preclinical and clinical trials, and ensuring regulatory compliance underscores his deep expertise.

Significant Research Contributions

His publication record highlights his research impact. For example, his work on the Emergence, Evolution, and Spread of Infectious Bronchitis Virus Genotype GI-23 published in Archives of Virology and Phylodynamic and Recombination Analyses published in Animals demonstrate his ability to conduct significant and relevant research. These studies have contributed to a better understanding of avian diseases, which is critical for advancing vaccine development.

Leadership in R&D

As a Scientific Affairs Manager, Mohamed has demonstrated leadership in research and development, particularly in vaccine design and production, including the implementation of complex R&D projects and ensuring compliance with European and Saudi regulations. His involvement in reviewing and approving the development and validation of analytical methods and in vivo vaccine testing protocols indicates a strong leadership role in research.

Ongoing Academic Pursuits

Mohamed is also pursuing a PhD in Veterinary Sciences with a focus on poultry diseases at Beni Suef University and Padua University, which further strengthens his qualifications as a researcher committed to advancing knowledge in his field.

Global Perspective

His involvement in research and clinical trials across different countries and his multilingual abilities (Arabic, English, and Italian) add a global perspective to his work, which is valuable in the context of a global award.

Conclusion

Given Mohamed Houta’s extensive research contributions, leadership in R&D, and ongoing academic pursuits, he is a suitable candidate for the Research for Best Researcher Award. His work not only advances public health through vaccine development but also contributes significantly to the global understanding of avian diseases.

Publication top notes

The emergence, evolution and spread of infectious bronchitis virus genotype GI-23

Phylodynamic and recombination analyses of avian infectious bronchitis GI-23 reveal a widespread recombinant cluster and new among-countries linkages

COVID-19: Risk assessment and mitigation measures in healthcare and non-healthcare workplaces

Infection with Avian Coronaviruses: A recurring problem in turkeys

Dall’Est all’Ovest: ricostruzione filodinamica della storia della variante 2 del virus della bronchite infettiva aviare